Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab
收藏NIAID Data Ecosystem2026-03-08 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2169449
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to assess the efficacy of single-agent regorafenib in the second-line treatment in metastatic colorectal cancer with any RAS or BRAF mutation previously treated with FOLFOXIRI plus bevacizumab in terms of progression-free survival at 6 months.
创建时间：
2014-06-15
